AlphaMadera's AlphaVal page computes Aktis Oncology, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag AKTS as undervalued, fairly valued, or overvalued.

What is Aktis Oncology, Inc.'s fair value?

Fair value for AKTS is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value AKTS?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from AKTS's most recent reported fundamentals.

AKTS - Aktis Oncology, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $33.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: AKTS has had negative net income and negative EPS in all 4 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.